NCT01913002

Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

Randomized, Double-blind, Placebo-controlled, Positive-controlled, 4-period, 4-way Crossover Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 800 mg and 2000 mg Compared With Placebo and Open-label Moxifloxacin in Healthy Subjects: A Thorough QT Study

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Lexicon Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This Phase 1 study is to investigate the effects of higher doses of LX4211 (800 mg and 2000 mg) do not differ from placebo in the mean change in QTcI from Baseline in healthy subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LX4211 800 mg
DRUG	LX4211 2000 mg
DRUG	moxifloxacin 400 mg
DRUG	LX4211 Placebo

Timeline

• Start date: 2013-07-01
• Primary completion: 2013-10-01
• First posted: 2013-07-31
• Last updated: 2013-10-30

Locations

1 site across 1 country: United States